Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Patent Suit Against Complete Genomics Moves to California, Enters Arbitration Program


This story was originally published Dec. 20.

Illumina's patent infringement lawsuit against Complete Genomics has been moved from the District of Delaware to the Northern District of California and has been assigned to a magistrate judge. In addition, the case is entering an arbitration program, according to a court order filed this month.

Illumina filed the suit in August in the US District Court for the District of Delaware, alleging that Complete Genomics infringes three of its patents, US Patents Nos. 6,306,597; 7,232,656; and 7,598,035 (IS 8/10/2010).

Complete Genomics filed a countersuit in September, denying any infringement and claiming that the three patents are invalid or unenforceable. It also requested to move the case from Delaware to California, where both companies have their business headquarters (IS 10/5/2010).

An initial case management conference is currently scheduled for March 15, 2011.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.